|Videos|August 1, 2020
Robert Busch, MD: EMPEROR-Reduced Topline Data and SGLT2 Class
Author(s)Patrick Campbell
A practicing endocrinologist discusses his reaction to topline results from EMPEROR-REDUCED and what he hopes to see in the presentation at ESC 2020.
Advertisement
Hear from Robert Busch, MD, as he offers his thoughts on the topline results of EMPEROR-REDUCED. Released on June 30, topline results of the study indicate use of empagliflozin (Jardiance) was associated with a reduction in the composite endpoint of death and worsening heart failure.
Scheduled to be presented almost one year after the results of DAPA-HF, full results of EMPEROR-REDUCED could definitively prove the benefit seen on heart failure is truly a class effect of SGLT2 inhibitors.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
VESALIUS-CV: Evolocumab Prevents Cardiovascular Disease in High-Risk Diabetes
2
Socrodeucitinib Meets Primary Endpoint in Phase 2 Psoriasis Study
3
New Liver Cancer BEACON-HCC Framework Shows 96.6% Concordance in Pilot
4
After Sickle Cell Gene Therapy, What Comes Next?
5




































































